- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07589075
Sodium-Glucose Co-Transporter-2 Inhibitors as Adjuvant Therapy With Letrozole in Induction of Ovulation (SGLT-2/PCOS)
Sodium-Glucose Co-Transporter-2 Inhibitors as Adjuvant Therapy With Letrozole in Induction of Ovulation in Women With Polycystic Ovarian Syndrome
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The study will be a randomized controlled clinical trial. Once the eligibility from screening visit is determined prior to baseline visit, randomization will be made by computer randomization for women who are admitted to Beni-Suef University Hospital. The Sample size will be 500 divided equally into 4 groups calculated with power=0.8.
Before initiation of the study, the population will be divided randomly into 4 equal groups: group A, B, C and D. The adjuvant therapy of each group will be group (A) Metformin , group (B) Dapagliflozin , Group(C) Combined Dapagliflozin-Metformin and group (D) with no adjuvant therapy (control group). The adjuvant therapy will be taken once daily with a main meal and started one month before initiation of letrozole. All groups will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
Ovulation rate (percentage of ovulatory cycles in the whole follow up period),Pregnancy rate (clinical pregnancy will be considered when an intrauterine gestational sac is seen and presence of a fetal heartbeat),Serum progesterone on day 21,Endometrial thickness at the time of ovulation and Weight, waist/hip ratio, height and body mass index (BMI) will be measured
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
-
Banī Suwayf, Egypte, 62517
- Gynecology and Reproductive department in Beni-Suef University Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
Pre-menopausal women aged 20-40 with primary or secondary infertility and PCOS which render them unable to become pregnant. Diagnosis of PCOS will based on European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine (ESHRE/ASRM) criteria, the diagnosis is made when at least two of the following criteria are met: oilgo and/or anovulation (infrequent or no ovulation), clinical and/or biochemical signs of hyperandrogenism including hirsutism, acne and/or increased testosterone levels or polycystic ovaries on ultrasound (defined as those containing at least 12 follicles measuring 2-9 mm in diameter arranged peripherally around an echo-dense stroma and/or with increased ovarian volume of at least 10 ml).
Exclusion Criteria:
Other causes of hyperandrogenism mimic PCOS such as congenital adrenal hyperplasia, Cushing's syndrome, or androgen secreting tumors are excluded.
Persistent hyperprolactinemia, thyroid dysfunction defined as TSH < 0.2 mIU/ML or >5.5 mIU/mL) or patients with menopausal levels of FSH (> 15 mIU/mL) (A normal level within the last year is adequate for enter the study).
Liver disease is defined as AST or ALT > 2 times normal or total bilirubin >2.5 mg/dL, kidney disease defined as BUN > 30 mg/dL or serum creatinine> 1.4 mg/dL or significant anemia defined as Hemoglobin < 10 mg/dL.
Women with Type I or II diabetes mellitus who are poorly controlled (defined as a HA1c level > 7.0%).
Untreated poorly controlled hypertension is defined as a systolic blood pressure ≥ 160 mm Hg or a diastolic ≥ 100 mm Hg obtained on two measures obtained at least 60 minutes apart.
History of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident.
Women who have undergone a bariatric surgery procedure in the recent past (<12 months) and are in a period of acute weight loss or have been advised against pregnancy by their bariatric surgeon.
Presence of any urinary symptom such as frequency, urgency, or bloody micturition.
In case of metabolic acidosis, osteoporosis, endometrial hyperplasia, or endometrial neoplasia.
Women who had gonadotropin induction, ovarian drilling before or women with hypergonadotropic hypogonadism or functional ovarian cysts (> 5cm).
Criteria of IVF/ICSI as poor Response, no Eggs or ectopic pregnancy. Women who receive antidiabetic medications such as insulin, thiazolidinediones, acarbose, or sulfonylureas are likely to confound the effects of study medication or who are currently receiving metformin XR for a diagnosis of Type I or Type II diabetes or for PCOS are also specifically excluded.
Concomitant use of medication that could interfere with the absorption, metabolism, and excretion of drugs involved in the study as the use of Furosemide, cimetidine increase metformin concentration and nifedipine enhances the absorption of metformin.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: "metformin"
will take Metformin 1000mg as adjuvant therapy
|
will take Metformin 1000 mg once daily with a main meal and started one month before initiation of the first cycle of induction.
will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
|
|
Expérimental: "Dapagliflozin"
will take Dapagliflozin 10mg as adjuvant therapy
|
will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
will take Dapagliflozin 10mg once daily with a main meal and started one month before initiation of the first cycle of induction.
|
|
Expérimental: "Dapagliflozin-Metformin"
will take combined Dapagliflozin-Metformin 5/1000 as adjuvant therapy
|
will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
will take Combined Dapagliflozin-Metformin 5/1000mg once daily with a main meal and started one month before initiation of the first cycle of induction.
|
|
Autre: "control"
will take letrozole 2.5mg the no adjuvant therapy
|
will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Ovulation rate
Délai: "through study completion, an average of 1 year".
|
percentage of ovulatory cycles
|
"through study completion, an average of 1 year".
|
|
Pregnancy rate
Délai: "through study completion, an average of 1 year".
|
when an intrauterine gestational sac is seen and presence of a fetal heartbeat)
|
"through study completion, an average of 1 year".
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Serum progesterone
Délai: "through study completion, an average of 1 year".
|
Serum progesterone
|
"through study completion, an average of 1 year".
|
|
Endometrial thickness
Délai: "through study completion, an average of 1 year".
|
Endometrial thickness
|
"through study completion, an average of 1 year".
|
|
Weight
Délai: "through study completion, an average of 1 year".
|
Weight in kilogram
|
"through study completion, an average of 1 year".
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IORG2226240
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .